Individuals with monoclonal B-cell lymphocytosis (MBL) have a 92% elevated risk of developing melanoma, new research shows. MBL, which has previously been shown to be a precursor to chronic lymphocytic leukemia (CLL), affects an estimated 8-10 million Americans over age 40.
Researchers followed 7,000 people screened for MBL through the Mayo Clinic Biobank over approximately four years. Even individuals with low levels of MBL appear to have an increased risk for melanoma, suggesting that presence of the condition could serve as a biomarker for early detection of melanoma. The researchers have also found that people with MBL are at higher risk of cancers originating in the lymphatic system and for hospitalizations due to serious infections including from COVID-19.
Although the research team is still studying the relationship between MBL, CLL, and melanoma—including research into shared genetic pathways—they encourage individuals with MBL to get annual skin exams and to use UV protection measures. Currently, patients with CLL are encouraged to get annual skin cancer screenings and use UV protection.
Findings appear in the Journal of Clinical Oncology.
The post White Blood Cell Disease Linked to Higher Melanoma Risk appeared first on Dermatology Education Foundation.